| 查看: 772 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
材料工程085601，270求调剂
已经有24人回复
-
085404 293求调剂
已经有3人回复
-
调剂
已经有21人回复
-
复试调剂，一志愿郑州大学材料与化工289分
已经有15人回复
-
08工科求调剂290分
已经有12人回复
-
286求调剂
已经有16人回复
-
材料类284调剂
已经有24人回复
-
考研调剂-材料类-284
已经有14人回复
-
327求调剂
已经有11人回复
-
一志愿985初试354分生物调剂
已经有3人回复
» 抢金币啦！回帖就可以得到:
-
物理学 调剂
+1/91
-
★★爆★★河北大学分析化学专业，强势学科，捡漏了，0703化学考生均可填报调剂
+1/91
-
杭州师范大学张龙课题组招诚聘有机合成，光电催化，理论计算与人工智能化学方向博士后
+1/86
-
材料与化工专业有大量调剂指标
+1/50
-
大连大学-六盘水师范学院联合培养研究生接收调剂
+2/44
-
延安大学化学与化工学院接收调剂生（化学、化工学硕和材料与化工专硕）
+5/35
-
【轻松准入】【生物医药】2026青岛大学招博士生
+1/18
-
C13、N15稳定同位素标记植物，助力科研人高效开展试验
+1/13
-
浙江农林大学 林业与生物技术学院 生物学(生物化学与分子生物学) 第一轮调剂生招生
+1/13
-
欢迎大家调剂----211大连海事大学双一流专业接受调剂
+1/11
-
香港科技大学 机器人/生物医学
+1/9
-
河南理工大学化学化工学院招收材料、化工类专业调剂研究生
+1/7
-
广东医科大学（东莞松山湖校区）生物医学工程学术型硕士接收调剂！
+1/6
-
太原科技大学材料科学与工程学院“03高性能轻质合金及新能源材料”学硕与专硕有缺额
+1/5
-
中南大学材料学院李明教授课题组招收2026年全日制学术型博士生
+1/5
-
【上海调剂】985联合培养！别错过能送你去丹麦/交大/同济/中科院的神仙导师！
+1/4
-
长江师范学院化学化工学院化学工程方向接收大量调剂考生
+1/4
-
差旅首选:第一次出差佛山开住宿餐饮发票实体店电子专用,保姆级教程请收好
+1/2
-
河北大学招收等离子体物理调剂生
+1/2
-
南通大学-交通与土木工程学院 招调剂学生
+1/1
7楼2011-01-10 13:40:17
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
|
b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. 术后48小时但不超过5天未使用抗生素所得的腹内脓肿（包括肝，脾）的患者，其脓肿是由于感染所引起的 |
8楼2011-01-12 10:42:52
